Differences Between Stavudine and Tenofovir Each Combined With Lamivudine and Efavirenz in SA HIV-infected Patients (CHRU01)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01601899 |
Recruitment Status
:
Terminated
(DSMB decision to begin closeout process in view of April 2010 SA HAART guideline)
First Posted
: May 18, 2012
Last Update Posted
: May 18, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Even with the benefits of HIV therapy, there is a possibility that HIV-infected individuals develop metabolic complications once they initiate treatment, which may also ultimately put them at a risk for impending heart disease in the next decades.
The main mechanism through which the main HIV drugs are thought to cause these metabolic changes and organ toxicities is mitochondrial toxicity. Most of studies that have been done, have taken place in the West, but few, if any, have been done in South Africa.
The purpose of this study is to prospectively identify early changes between the two different drugs, Stavudine and Tenofovir, to assess their virological response, molecular, biochemical and clinical picture, and the possible associated change in cardiovascular risk factors, this, in the South African setting, and make recommendations to modify the current National AIDS role out programme
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Mitochondrial Toxicity Metabolic Complications | Drug: Stavudine Drug: Tenofovir | Phase 4 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 60 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Molecular, Biochemical and Clinical Differences Between Stavudine and Tenofovir, Each Combined With Lamivudine and Efavirenz in South African HIV-infected Patients |
Study Start Date : | October 2008 |
Actual Primary Completion Date : | October 2010 |
Actual Study Completion Date : | December 2010 |

Arm | Intervention/treatment |
---|---|
Active Comparator: ARM A
Stavudine (d4T) 30 mg po BD if wt < 60kg, or 40 mg po BD if wt > 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
|
Drug: Stavudine
30 mg po BD if wt < 60kg, or 40 mg po BD if wt > 60kg
Other Names:
|
Active Comparator: ARM B
Stavudine (d4T) 20 mg po BD if wt < 60kg, or 30 mg po BD if wt > 60kg PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
|
Drug: Stavudine
20 mg po BD if wt < 60kg, or 30 mg po BD if wt > 60kg
Other Names:
|
Active Comparator: ARM C
TDF 300 mg po QD PLUS Lamivudine (3TC) 150mg po BD PLUS Efavirenz 600mg po nocte
|
Drug: Tenofovir
300 mg po QD
Other Names:
|
- changes in mitochondrial DNA copy number in adipocyte tissue [ Time Frame: from baseline to 4 weeks ]
- changes in gene expression in adipocyte tissue [ Time Frame: from baseline to 4 weeks ]
- changes in lipid levels [ Time Frame: from baseline to 4 weeks ]
- changes in glycaemic indices [ Time Frame: from baseline to 4 weeks ]
- changes in adipocytokines [ Time Frame: from baseline to 4 weeks ]
- changes in lipid levels [ Time Frame: from baseline to 48 weeks ]
- changes in glycaemic indices [ Time Frame: from baseline to 48 weeks ]
- changes in adipocytokines [ Time Frame: from baseline to 48 weeks ]
- Time from randomization to virologic failure [ Time Frame: up to 48 weeks ]
- Time from randomization to death [ Time Frame: up to 48 weeks ]
- time from randomization to the first adverse event requiring discontinuation of any of the drugs that formed the initial regimen [ Time Frame: up to 48 weeks ]
- time from randomization to the first Grade 3 or higher adverse event. [ Time Frame: up to 48 weeks ]
- Time from randomization to HIV-related disease progression (defined as progression to WHO Clinical Stage 3 or 4) [ Time Frame: up to 48 weeks ]
- Adherence to study drug regimens as assessed by participant self-report and pill count. [ Time Frame: up to 48 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- HIV-1 infection, documented by a rapid HIV test or any licensed ELISA test kit, and confirmed by either a second rapid HIV test or an ELISA consistent with the Themba Lethu Clinic guidelines.
- Age >/= 18 years,
- CD4+ cell count < 200 cells/mm3.
-
The following laboratory values obtained within 45 days prior to study entry:
- Absolute neutrophil count (ANC) ≥ 750/mm3
- Hemoglobin ≥ 7.0 g/dL
- Platelet count ≥ 50,000/mm3
- AST (SGOT), ALT (SGPT), and alkaline phosphatase ≤ 2.5 x ULN
- Total bilirubin ≤ 2.5 x ULN
-
Evidence of normal renal function within 45 days prior to study entry as determined by an estimated creatinine clearance of ≥60 mL/min using the Cockcroft-Gault formula:
{[140 - age (yr)] x [weight (kg)] ÷ [72 x serum Cr (mg/dL)]} (X 0.85 in females.)
- Participants of reproductive age (defined as girls who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months, i.e. who have had menses within the preceding 24 months), or who have not undergone surgical sterilization (e.g. hysterectomy, or bilateral oophorectomy or salpingotomy) must have a negative serum or urine pregnancy test within 45 days prior to study entry.
-
Participants of reproductive potential, must be willing to abstain from participation in a conception process (e.g. active attempt to become pregnant or in vitro fertilization). If participants are sexual active, that could lead to pregnancy, they must use at least one reliable form of contraception listed below while receiving protocol-specified medications and for 6 weeks after stopping the medication.
- Male or female condoms with or without a spermicidal agent (condoms are recommended because their appropriate use is the only contraception method effective for preventing HIV transmission).
- Diaphragm or cervical cap with spermicide
- IUD
- Hormonal-based contraception
- Possible interactions of study drugs with estrogen-based contraceptives: LPV/RTV decrease plasma levels of ethinyl estradiol; therefore, estrogen-based contraceptives are not reliable for women receiving LPV/RTV and an alternative contraception method must be used.
- NOTE: Participants who are not of reproductive potential (girls who have not reached menarche, women who have been post-menopausal for at least 24 consecutive months) girls and women who are not participating in sexual activity that could lead to pregnancy, or women who have undergone surgical sterilization, (e.g. hysterectomy, or bilateral oophorectomy or salpingotomy) are eligible without requiring the use of contraception.
- Ability and willingness of participant
- Intent to remain in current geographical area of residence for the duration of study.
- Willingness to attend study visits as required by the study.
Exclusion Criteria:
- Receipt of any antiretrovirals (including for purposes of occupational or sexual post exposure prophylaxis), except for SD Nevirapine taken within six months.
- Use of systemic cancer chemotherapy, systemic investigational agents, immunomodulators (growth factors, systemic corticosteroids, HIV vaccines, immune globulin, interleukins, interferons) or rifampin within 30 days prior to study entry.
- Breastfeeding or pregnancy.
- Allergy to study drugs.
- Any condition, including active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
- Any serious illness requiring systemic treatment and/or hospitalization until participant either completes therapy or is clinically stable on therapy, in the opinion of the investigator, for at least 30 days prior to study entry.
- Involuntary incarceration in a correctional facility, for legal reasons or in a medical facility for treatment of either a psychiatric or physical (e.g., infectious disease) illness.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01601899
South Africa | |
Themba Lethu Clinic, Helen Joseph Hospital, Auckland Park | |
Johannesburg, Gauteng, South Africa, 2006 |
Principal Investigator: | Colin N Menezes, FCP(SA) | Clinical HIV Research Unit, University of the Witwatersrand | |
Study Director: | Ian Sanne, FCP(SA) | Clinical HIV Research Unit, University of the Witwatersrand |
Responsible Party: | Colin Menezes, Consultant Infectious Diseases Physician and Lecturer, University of Witwatersrand, South Africa |
ClinicalTrials.gov Identifier: | NCT01601899 History of Changes |
Other Study ID Numbers: |
CHRU01 |
First Posted: | May 18, 2012 Key Record Dates |
Last Update Posted: | May 18, 2012 |
Last Verified: | May 2012 |
Keywords provided by Colin Menezes, University of Witwatersrand, South Africa:
trial stavudine tenofovir mitochondria |
insulin resistance lipids HOMA |
Additional relevant MeSH terms:
Tenofovir Lamivudine Efavirenz Stavudine Antiviral Agents Anti-Infective Agents Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
Anti-Retroviral Agents Anti-HIV Agents Cytochrome P-450 CYP2C9 Inhibitors Cytochrome P-450 Enzyme Inhibitors Cytochrome P-450 CYP2C19 Inhibitors Cytochrome P-450 CYP2B6 Inducers Cytochrome P-450 Enzyme Inducers Cytochrome P-450 CYP3A Inducers Antimetabolites |